Non-Small Cell Lung Cancer, Version 6.2015

David S. Ettinger, Douglas E. Wood, Wallace Akerley, Lyudmila A. Bazhenova, Hossein Borghaei, David R oss Camidge, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D'Amico, Todd L. Demmy, Thomas J. Dilling, M. Chris Dobelbower, Ramaswamy Govindan, Frederic W. Grannis, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Lee M. Krug, Rudy P. Lackner, Michael Lanuti & 18 others Rogerio Lilenbaum, Jules Lin, Billy W. Loo, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, Steven E. Schild, Theresa A. Shapiro, Scott J. Swanson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, Miranda Hughes, National comprehensive cancer network

Research output: Contribution to journalArticle

230 Citations (Scopus)

Abstract

These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC). Appropriate targeted therapy is very effective in patients with advanced NSCLC who have specific genetic alterations. Therefore, it is important to test tumor tissue from patients with advanced NSCLC to determine whether they have genetic alterations that make them candidates for specific targeted therapies. These NCCN Guidelines Insights describe the different testing methods currently available for determining whether patients have genetic alterations in the 2 most commonly actionable genetic alterations, notably anaplastic lymphoma kinase (ALK) gene rearrangements and sensitizing epidermal growth factor receptor (EGFR) mutations.

Original languageEnglish (US)
Pages (from-to)515-524
Number of pages10
JournalJournal of the National Comprehensive Cancer Network : JNCCN
Volume13
Issue number5
StatePublished - May 1 2015

Fingerprint

Non-Small Cell Lung Carcinoma
Guidelines
Gene Rearrangement
Epidermal Growth Factor Receptor
Mutation
Therapeutics
Neoplasms
anaplastic lymphoma kinase

ASJC Scopus subject areas

  • Oncology

Cite this

Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R. O., ... National comprehensive cancer network (2015). Non-Small Cell Lung Cancer, Version 6.2015. Journal of the National Comprehensive Cancer Network : JNCCN, 13(5), 515-524.

Non-Small Cell Lung Cancer, Version 6.2015. / Ettinger, David S.; Wood, Douglas E.; Akerley, Wallace; Bazhenova, Lyudmila A.; Borghaei, Hossein; Camidge, David R oss; Cheney, Richard T.; Chirieac, Lucian R.; D'Amico, Thomas A.; Demmy, Todd L.; Dilling, Thomas J.; Dobelbower, M. Chris; Govindan, Ramaswamy; Grannis, Frederic W.; Horn, Leora; Jahan, Thierry M.; Komaki, Ritsuko; Krug, Lee M.; Lackner, Rudy P.; Lanuti, Michael; Lilenbaum, Rogerio; Lin, Jules; Loo, Billy W.; Martins, Renato; Otterson, Gregory A.; Patel, Jyoti D.; Pisters, Katherine M.; Reckamp, Karen; Riely, Gregory J.; Rohren, Eric; Schild, Steven E.; Shapiro, Theresa A.; Swanson, Scott J.; Tauer, Kurt; Yang, Stephen C.; Gregory, Kristina; Hughes, Miranda; National comprehensive cancer network.

In: Journal of the National Comprehensive Cancer Network : JNCCN, Vol. 13, No. 5, 01.05.2015, p. 515-524.

Research output: Contribution to journalArticle

Ettinger, DS, Wood, DE, Akerley, W, Bazhenova, LA, Borghaei, H, Camidge, DRO, Cheney, RT, Chirieac, LR, D'Amico, TA, Demmy, TL, Dilling, TJ, Dobelbower, MC, Govindan, R, Grannis, FW, Horn, L, Jahan, TM, Komaki, R, Krug, LM, Lackner, RP, Lanuti, M, Lilenbaum, R, Lin, J, Loo, BW, Martins, R, Otterson, GA, Patel, JD, Pisters, KM, Reckamp, K, Riely, GJ, Rohren, E, Schild, SE, Shapiro, TA, Swanson, SJ, Tauer, K, Yang, SC, Gregory, K, Hughes, M & National comprehensive cancer network 2015, 'Non-Small Cell Lung Cancer, Version 6.2015', Journal of the National Comprehensive Cancer Network : JNCCN, vol. 13, no. 5, pp. 515-524.
Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DRO et al. Non-Small Cell Lung Cancer, Version 6.2015. Journal of the National Comprehensive Cancer Network : JNCCN. 2015 May 1;13(5):515-524.
Ettinger, David S. ; Wood, Douglas E. ; Akerley, Wallace ; Bazhenova, Lyudmila A. ; Borghaei, Hossein ; Camidge, David R oss ; Cheney, Richard T. ; Chirieac, Lucian R. ; D'Amico, Thomas A. ; Demmy, Todd L. ; Dilling, Thomas J. ; Dobelbower, M. Chris ; Govindan, Ramaswamy ; Grannis, Frederic W. ; Horn, Leora ; Jahan, Thierry M. ; Komaki, Ritsuko ; Krug, Lee M. ; Lackner, Rudy P. ; Lanuti, Michael ; Lilenbaum, Rogerio ; Lin, Jules ; Loo, Billy W. ; Martins, Renato ; Otterson, Gregory A. ; Patel, Jyoti D. ; Pisters, Katherine M. ; Reckamp, Karen ; Riely, Gregory J. ; Rohren, Eric ; Schild, Steven E. ; Shapiro, Theresa A. ; Swanson, Scott J. ; Tauer, Kurt ; Yang, Stephen C. ; Gregory, Kristina ; Hughes, Miranda ; National comprehensive cancer network. / Non-Small Cell Lung Cancer, Version 6.2015. In: Journal of the National Comprehensive Cancer Network : JNCCN. 2015 ; Vol. 13, No. 5. pp. 515-524.
@article{5dc19a3902124a9fb1a8b5c838dd74bf,
title = "Non-Small Cell Lung Cancer, Version 6.2015",
abstract = "These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC). Appropriate targeted therapy is very effective in patients with advanced NSCLC who have specific genetic alterations. Therefore, it is important to test tumor tissue from patients with advanced NSCLC to determine whether they have genetic alterations that make them candidates for specific targeted therapies. These NCCN Guidelines Insights describe the different testing methods currently available for determining whether patients have genetic alterations in the 2 most commonly actionable genetic alterations, notably anaplastic lymphoma kinase (ALK) gene rearrangements and sensitizing epidermal growth factor receptor (EGFR) mutations.",
author = "Ettinger, {David S.} and Wood, {Douglas E.} and Wallace Akerley and Bazhenova, {Lyudmila A.} and Hossein Borghaei and Camidge, {David R oss} and Cheney, {Richard T.} and Chirieac, {Lucian R.} and D'Amico, {Thomas A.} and Demmy, {Todd L.} and Dilling, {Thomas J.} and Dobelbower, {M. Chris} and Ramaswamy Govindan and Grannis, {Frederic W.} and Leora Horn and Jahan, {Thierry M.} and Ritsuko Komaki and Krug, {Lee M.} and Lackner, {Rudy P.} and Michael Lanuti and Rogerio Lilenbaum and Jules Lin and Loo, {Billy W.} and Renato Martins and Otterson, {Gregory A.} and Patel, {Jyoti D.} and Pisters, {Katherine M.} and Karen Reckamp and Riely, {Gregory J.} and Eric Rohren and Schild, {Steven E.} and Shapiro, {Theresa A.} and Swanson, {Scott J.} and Kurt Tauer and Yang, {Stephen C.} and Kristina Gregory and Miranda Hughes and {National comprehensive cancer network}",
year = "2015",
month = "5",
day = "1",
language = "English (US)",
volume = "13",
pages = "515--524",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "5",

}

TY - JOUR

T1 - Non-Small Cell Lung Cancer, Version 6.2015

AU - Ettinger, David S.

AU - Wood, Douglas E.

AU - Akerley, Wallace

AU - Bazhenova, Lyudmila A.

AU - Borghaei, Hossein

AU - Camidge, David R oss

AU - Cheney, Richard T.

AU - Chirieac, Lucian R.

AU - D'Amico, Thomas A.

AU - Demmy, Todd L.

AU - Dilling, Thomas J.

AU - Dobelbower, M. Chris

AU - Govindan, Ramaswamy

AU - Grannis, Frederic W.

AU - Horn, Leora

AU - Jahan, Thierry M.

AU - Komaki, Ritsuko

AU - Krug, Lee M.

AU - Lackner, Rudy P.

AU - Lanuti, Michael

AU - Lilenbaum, Rogerio

AU - Lin, Jules

AU - Loo, Billy W.

AU - Martins, Renato

AU - Otterson, Gregory A.

AU - Patel, Jyoti D.

AU - Pisters, Katherine M.

AU - Reckamp, Karen

AU - Riely, Gregory J.

AU - Rohren, Eric

AU - Schild, Steven E.

AU - Shapiro, Theresa A.

AU - Swanson, Scott J.

AU - Tauer, Kurt

AU - Yang, Stephen C.

AU - Gregory, Kristina

AU - Hughes, Miranda

AU - National comprehensive cancer network

PY - 2015/5/1

Y1 - 2015/5/1

N2 - These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC). Appropriate targeted therapy is very effective in patients with advanced NSCLC who have specific genetic alterations. Therefore, it is important to test tumor tissue from patients with advanced NSCLC to determine whether they have genetic alterations that make them candidates for specific targeted therapies. These NCCN Guidelines Insights describe the different testing methods currently available for determining whether patients have genetic alterations in the 2 most commonly actionable genetic alterations, notably anaplastic lymphoma kinase (ALK) gene rearrangements and sensitizing epidermal growth factor receptor (EGFR) mutations.

AB - These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC). Appropriate targeted therapy is very effective in patients with advanced NSCLC who have specific genetic alterations. Therefore, it is important to test tumor tissue from patients with advanced NSCLC to determine whether they have genetic alterations that make them candidates for specific targeted therapies. These NCCN Guidelines Insights describe the different testing methods currently available for determining whether patients have genetic alterations in the 2 most commonly actionable genetic alterations, notably anaplastic lymphoma kinase (ALK) gene rearrangements and sensitizing epidermal growth factor receptor (EGFR) mutations.

UR - http://www.scopus.com/inward/record.url?scp=84984590308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984590308&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 515

EP - 524

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 5

ER -